Alkegen Battery Group Will Exhibit at AABC Europe in Mainz, and The Battery Show in Stuttgart, Germany this June
Alkegen, a leading specialty materials platform creating transformational battery materials, today announced they will be exhibiting at the upcoming AABC Europe Conference in Mainz, and The Battery Show Europe in Stuttgart, Germany. Alkegen’s Battery Group focuses on delivering battery innovation with advanced materials for Lithium Ion Battery (LiB) thermal barriers and electrical protection, battery separator technology, and revolutionary silicon fiber anode battery material (SiFAB®) that enables greater energy density, faster charges, and longer battery life in electric vehicles, portable electronics and energy storage systems. Alkegen, formerly Unifrax and Lydall, is a one-of-a-kind specialty materials platform dedicated to human health and sustainability.
The technical capabilities of the Alkegen Battery Group support customer partnerships with a global engineering team, deep technical expertise, and customer collaboration. These unique capabilities allow for a globally coordinated team of engineers and designers with a dedicated presence in each region, solutions designed for easy installation and handling, and scalable, customized solutions that meet budgets and optimize performance.
Alkegen’s range of technical capabilities includes Design, Testing, Prototyping and Serial Production. The global design team employs 3D modelling software to collaborate with customers and optimize form, fit and function. Thermal, mechanical, environmental and compression testing are used for part validation and new product development. The engineering team prototypes both in-pack and in-cell solutions once designed to validate product functionality. Finally, Alkegen’s global footprint of IATF certified sites and engineering teams support scale up through regional production locations in Europe, North America and the Asia-Pacific region.
Alkegen’s transformational battery portfolio includes both in-cell and in-pack solutions. In-cell solutions such as separators and additives to improve cell performance and safety include SiFAB, Alkegen’s fibrous silicon anode battery material with ultra-high capacity that enables greater energy density and is highly scalable. SiFAB technology was launched last year and will scale to production this summer. Also from Alkegen, Inovion™ is a high surface area fibrous separator paper that promotes rapid ion exchange. Alkegen also offers several in-pack solutions including high-temperature lightweight products designed to reduce thermal runaway propagation along with providing mechanical, electrical and thermal protections within the battery pack. Innovative product solutions also include FyreBlocker™ LiB, AlkeGel™ Aerogel Materials and FyreWrap® LiB performance materials. These in-cell and in-pack innovations have valuable functions in numerous industries and applications from portable electronics, e-mobility, to robotics.
”Alkegen’s Battery Group is focused on delivering the latest battery technologies and developments from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Adam Kelsall, General Manager, Alkegen Battery Group. “This transformational portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium-ion battery fire protection, creating greater battery energy density and delivering longer battery life in both electric vehicles and consumer electronics,” said Kelsall.
Alkegen will be available to discuss these innovative new battery materials and more during the 2022 AABC Europe Show June 13-15, in Mainz, and The Battery Show June 28-30, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at firstname.lastname@example.org.
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen is vertically integrated across multiple process technology platforms designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology27.6.2022 07:00:00 CEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients. The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor, which was granted Accelerated Approval by the U.S. Food and Drug Administratio
The Group Announces the Beginning of An Open-Ended Share Repurchase Programme Of Prosus And Naspers Shares27.6.2022 06:00:00 CEST | Press release
The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin selling small numbers of ordinary shares in Tencent Holdings Limited (“Tencent”) held by the Group (“Tencent Shares”) regularly and in an orderly manner, while concurrently purchasing Prosus Shares and Naspers Shares pursuant to the Repurchase Programme, as long as the Group
The Group Announces the Beginning of an Open-Ended Share Repurchase Programme of Prosus and Naspers Shares27.6.2022 06:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INTO OR IN ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT NOTICE AND DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT. The board of directors of Naspers Limited ("Naspers Board") (JSE: NPN; LSE: NPSN) and board of directors ("Prosus Board") of Prosus N.V. ("Prosus") (Euronext Amsterdam: PRX; JSE: PRX) are pleased to announce the beginning of an open-ended, repurchase programme in respect of the ordinary shares N in the capital of Prosus ("Prosus Shares") and N ordinary shares ("Naspers Shares") in the share capital of Naspers, from the respective Prosus and Naspers (together the "Group") free-float shareholders (together the "Repurchase Programme"). The Repurchase Programme is expected to efficiently unlock immediate value for the shareholders of Prosus ("Prosus Shareholders") and Naspers ("Naspers Shareholders"). Prosus will begin sellin
EPPA : New Study Shows That Making Reusable Containers for Takeaway Obligatory Will Undermine the EU’s Environmental Goals27.6.2022 06:00:00 CEST | Press release
Obligatory reusable packaging in takeaway services would be more burdensome for the environment than continuing to use single-use paper-based packaging. This is the conclusion of a new meta-study assessment, commissioned by the European Paper Packaging Alliance and carried out by renowned engineering consultancy, Ramboll. As the European Commission prepares to propose a revision of the Packaging and Packaging Waste Directive (PPWD) with potentially far-reaching implications, the analysis, which examined 26 scientific studies, shows that reuse systems impose exclusive additional burdens to the environment when compared to single-use, related to additional washing, take-back transportation and breakage / unit loss associated with takeaway. The results show that Climate Change is by far the most affected impact category when implementing reuse in take-away services, and that reusable tableware can also have a significant impact on water use. Commenting on the meta-study assessment, Eric L
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release
Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit